Horien Biotech (7814) was listed on the OTC market on the 16th. Benefiting from increased shipments of its core collagen medical devices, its consolidated revenue in June increased by 209.29% year-on-year, and its first-half revenue increased by 55.78% year-on-year. Furthermore, three of the company's collagen medical devices simultaneously obtained the highest-level Class 4 medical device marketing authorization from the Thai TFDA, further boosting its expansion in the ASEAN market.

 Horien stated that driven by growing demand in Taiwan, the United States, and overseas markets, shipments of regenerative medicine-related products continued to rise, pushing up June's revenue significantly and maintaining an upward trend in operations. With its official listing on the OTC market, the company will leverage capital market resources to accelerate product development, expand its global market presence, and enhance its brand competitiveness.

 With its operations steadily improving, Horien has obtained Class 4 (highest level) medical device marketing authorization from the Thai Food and Drug Administration (TFDA) for three of its products: "Horien Extracellular Membrane," "Horien Collagen Bone Graft Matrix," and "Horien Collagen Matrix." These products are primarily used in periodontal and bone tissue repair, filling of oral and maxillofacial bone defects, wound care, and hemostasis.

 The company stated that Thailand is a crucial medical and aesthetic market in Southeast Asia. Obtaining three Class 4 approvals at once signifies international regulatory recognition of product quality and R&D technology, and will help accelerate market penetration in Thailand. Further Class 3 medical device certifications in the Philippines and Vietnam are expected to be obtained subsequently, further completing its ASEAN footprint. In addition, its bio-ink products are planned for entry into the European market by the end of the year, continuing to expand its global operations.

 Haichang's independently developed "biodegradable ureteral stent" has obtained a Taiwanese invention patent and will subsequently apply for patents in the United States, Europe, and China. The product has completed sample development and entered the animal testing phase. The company points out that this product is expected to alleviate the clinical pain point of traditional ureteral stents requiring a second surgery for removal, possessing the potential to capture the high-end urological medical device market.

 In addition, collagen regeneration patches developed using decellularization technology have entered the pilot production stage, targeting the surgical and orthopedic tissue repair market, becoming a new growth driver for the future.

 To strengthen its supply chain layout, Haichang's subsidiary, Shengli Biotechnology, has signed a memorandum of understanding and cooperation agreement with Taiwan Sugar Corporation and Taiwan Livestock Corporation to establish a medical-grade raw material supply chain that complies with ISO 13485 medical device quality management system and ISO 22442 animal tissue medical device risk management standards. This will enhance its raw material self-sufficiency and support future global market expansion needs.

 Horien Chairman Tsai Kuo-Tien stated that listing on the stock exchange is an important milestone in the company's development. In the future, the company will continue to deepen its layout in dental and surgical medical devices, and promote operational growth through high-end regenerative medical devices and international market expansion. With the successive acquisition of overseas licenses and the gradual harvest of new products, the company's operations are expected to maintain steady growth.

Report Link:

Horien's listing on the over-the-counter market marks a 209% year-on-year increase in June revenue; three medical device licenses in Thailand support its overseas expansion.